These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20805677)

  • 1. [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
    Nakamura S; Yata K; Jinno T; Harada T; Fujii S; Miki H; Nakano A; Kagawa K; Takeuchi K; Ozaki S; Abe M; Matsumoto T
    Rinsho Ketsueki; 2010 Aug; 51(8):690-5. PubMed ID: 20805677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin.
    Suzuki K; Sugawara Y; Sekine T; Nakase K; Katayama N
    J Infect Chemother; 2009 Feb; 15(1):42-5. PubMed ID: 19280300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
    Terpos E; Politou M; Rahemtulla A
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
    Jaskiewicz AD; Herrington JD; Wong L
    Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
    Koda Y; Mori T; Shimizu T; Kato J; Yamane A; Sadahira K; Tsukada Y; Yokoyama K; Hashimoto N; Hattori Y; Okamoto S
    Rinsho Ketsueki; 2012 Aug; 53(8):760-4. PubMed ID: 22975816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Wang HH; Tsui J; Wang XY; Liu SS; Li J
    Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute pancreatitis caused by bortezomib.
    Solakoglu T; Akyol P; Guney T; Dilek I; Atalay R; Koseoglu H; Akin E; Demirezer Bolat A; Buyukasik NS; Ersoy O
    Pancreatology; 2013; 13(2):189-90. PubMed ID: 23561979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
    Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
    Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
    Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
    J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
    Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
    Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib-induced tumor lysis syndrome in multiple myeloma.
    Sezer O; Vesole DH; Singhal S; Richardson P; Stadtmauer E; Jakob C; Boral AL; Esseltine DL; Mehta J
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):233-5. PubMed ID: 17229340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
    Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
    J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia].
    Nagamachi Y; Yamauchi N; Muramatsu H; Okamoto T; Inomata H; Nozawa E; Koyama R; Ihara K; Nishisato T; Yamada H; Yano T; Tanaka S; Ono K; Kikuchi S; Kato J
    Rinsho Ketsueki; 2013 May; 54(5):451-6. PubMed ID: 23727683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib and bilateral herpes zoster.
    di Meo N; Bergamo S; Dondas A; Trevisan G
    Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.